Literature DB >> 4198200

Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component.

M Levin, M Pras, E C Franklin.   

Abstract

Antisera have been prepared against the major nonimmunoglobulin component of secondary and familial Mediterranean fever (FMF) associated amyloid which has been called A component or acid soluble fraction (ASF). The antisera were shown to be monospecific for ASF by precipitation of (125)I-labeled antigen and gave a reaction of identity with four different ASF preparations. The antisera were able to detect a circulating component in human serum that migrated in the alpha1-globulin region. This circulating component gave a line of identity with degraded ASF by double immunodiffusion. 57 normal sera and 89 sera from patients with diseases known to be frequently associated with amyloidosis were tested by immunodiffusion for the circulating ASF component. 7% of normal sera and 50-80% of the pathologic sera had elevated amounts of this component. Absorption studies showed that all normal sera probably have small amounts of this component while cord sera do not have detectable amounts. This component was partially purified and was shown to be slightly larger than albumin. The relation of the circulating component to the acid soluble fraction of amyloid is discussed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4198200      PMCID: PMC2139393          DOI: 10.1084/jem.138.2.373

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction.

Authors:  Z OVARY
Journal:  Prog Allergy       Date:  1958

2.  Zone electrophoresis.

Authors:  H G KUNKEL
Journal:  Methods Biochem Anal       Date:  1954

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  High specific activity labeling of protein with I-131 by the iodine monochloride method.

Authors:  W F Bale; R W Helmkamp; T P Davis; M J Izzo; R L Goodland; M A Contreras; I L Spar
Journal:  Proc Soc Exp Biol Med       Date:  1966-06

5.  Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses.

Authors:  G G Glenner; W Terry; M Harada; C Isersky; D Page
Journal:  Science       Date:  1971-06-11       Impact factor: 47.728

6.  The acid-soluble fraction of amyloid--a fibril forming protein.

Authors:  M Pras; T Reshef
Journal:  Biochim Biophys Acta       Date:  1972-06-22

7.  Antigenic determinants in amyloid deposits.

Authors:  E S Cathcart; M S Skinner; A S Cohen; O J Lawless; M D Benson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

8.  Antigenic and chemical characterization of non-immunoglobulin amyloid proteins.

Authors:  G Husby; K Sletten; T E Michaelsen; J B Natvig
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

9.  Creation of "amyloid" fibrils from Bence Jones proteins in vitro.

Authors:  G G Glenner; D Ein; E D Eanes; H A Bladen; W Terry; D L Page
Journal:  Science       Date:  1971-11-12       Impact factor: 47.728

10.  The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils.

Authors:  M Levin; E C Franklin; B Frangione; M Pras
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

View more
  52 in total

1.  Acceleration of amyloidosis by syngeneic spleen cells from normal donors.

Authors:  M Axelrad; R Kisilevsky; S Beswetherick
Journal:  Am J Pathol       Date:  1975-02       Impact factor: 4.307

2.  Serum amyloid A: evidence for its origin in polymorphonuclear leukocytes.

Authors:  C J Rosenthal; L Sullivan
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

3.  The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

Authors:  M L Baltz; D Caspi; B E Glatthaar; U Moser; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

4.  Amyloid fibril protein AA in Papua New Guinean amyloidosis.

Authors:  R F Anders; M A Price; I S Wilkey; G Husby; F Takitaki; J B Natvig; K P McAdam
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

5.  Mouse amyloid protein AA: Homology with nonimmunoglobulin protein of human and monkey amyloid substance.

Authors:  N Eriksen; L H Ericsson; N Pearsall; D Lagunoff; E P Benditt
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

6.  Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation.

Authors:  K P McAdam; R J Elin; J D Sipe; S M Wolff
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

7.  Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin.

Authors:  R P Linke; J D Sipe; P S Pollock; T F Ignaczak; G G Glenner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

8.  Amyloid-related serum component (protein ASC) IN LEPROSY PATIENTS.

Authors:  G Kronvall; G Husby; D Samuel; G Bjune; H Wheate
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

9.  Demonstration of AA-protein in formalin-fixed, paraffin-embedded tissues.

Authors:  S Shtrasburg; M Pras; P Langevitch; R Gal
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

10.  Amyloid protein SAA is associated with high density lipoprotein from human serum.

Authors:  E P Benditt; N Eriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.